By Business/Source
Currency:USD
2025/Q3
Stock NameRevenueRatio
Sale of the Company’s Oral and IV TPOXX® as well as research and development services2.62M100.00%
By Country/Region
Currency:USD
2024/FY
Stock NameRevenueRatio
United States115.74M83.44%
Asia-Pacific13.86M9.99%
Europe, Middle East and Africa (EMEA)8.38M6.04%
Canada737.68K0.53%